Company intelligence / Profile preview
Photopharmica
Leeds, West Yorkshire, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Photopharmica developed light-sensitive drugs for anti-infective and oncology indications using photosensitizers. Clinical trials included Phase II studies in acne vulgaris and chronic leg ulcers. The company was a University of Leeds spin-out with positive early clinical data but is now dissolved. No commercialized products.
- Therapeutic areas
- OncologyDermatologyInfectious Diseases
- Modalities
- Small moleculePhotosensitizer
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
IP Group held a significant stake (~49.9%); no major pharma partnerships disclosed.
Beyond the preview
Go deeper on Photopharmica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Photopharmica.